Evaluation of an Inflammation-based Prognostic Score (GPS) in Patients Undergoing Resection for Colon and Rectal Cancer
Overview
General Surgery
Affiliations
Background/aims: The aim of the study was to examine the value of the combination of an elevated C-reactive protein and hypoalbuminaemia (GPS) in predicting cancer-specific survival after resection for colon and rectal cancer.
Materials And Methods: The GPS was constructed as follows: Patients with both an elevated C-reactive protein (>10 mg/l) and hypoalbuminaemia (<35 g/l) were allocated a score of 2. Patients in whom only one or none of these biochemical abnormalities was present were allocated a score of 1 or 0, respectively.
Results: A GPS of 1 (n = 109) was mainly due to an elevated C-reactive protein concentration and the remainder due to hypoalbuminaemia. In those patients with a GPS of 1 due to hypoalbuminaemia (n = 16), the 3-year overall survival rate was 94% compared with 62% in those patients with a GPS of 1 due to an elevated C-reactive protein concentration (n = 93, p = 0.0094). Therefore, the GPS was modified such that patients with hypoalbuminaemia were assigned a score of 0 in the absence of an elevated C-reactive protein. On univariate analysis of those patients with colon and rectal cancer, the modified GPS (p < 0.0001) was significantly associated with overall and cancer specific survival. On univariate survival analysis of those patients with Dukes B colon and rectal cancer, the modified GPS (p < 0.01) was significantly associated with overall and cancer specific survival.
Conclusion: The results of the present study indicate that the GPS, before surgery, predicts overall and cancer-specific survival after resection of colon and rectal cancer.
Shibata K, Iwatani K, Imai Y, Yoshihara K, Miyajima K, Fukuokaya W In Vivo. 2025; 39(2):824-833.
PMID: 40010955 PMC: 11884453. DOI: 10.21873/invivo.13885.
Jin Z, Yang T, Wang Z BMC Gastroenterol. 2025; 25(1):99.
PMID: 39984877 PMC: 11844028. DOI: 10.1186/s12876-024-03583-3.
Jiang L, Jin W Int J Hematol. 2025; .
PMID: 39899232 DOI: 10.1007/s12185-025-03935-z.
Schleifenbaum J, Morgenthaler J, Sharma S, Klussmann J, Linde P, Wegen S Radiat Oncol. 2025; 20(1):1.
PMID: 39748422 PMC: 11697932. DOI: 10.1186/s13014-024-02570-y.
Skar E, Wendelbo O, Reikvam H EJHaem. 2024; 5(6):1223-1235.
PMID: 39691271 PMC: 11647729. DOI: 10.1002/jha2.1022.